LILRB

LILRB is a type I transmembrane glycoprotein belonging to the leukocyte immunoglobulin-like receptor (LILR) family, also known as the CD85, ILT, or LIR family. It is an immunosuppressive receptor. Its structure consists of an extracellular, transmembrane, and intracellular region: the extracellular region contains four immunoglobulin (Ig)-like domains responsible for ligand binding; the intracellular region contains the immunoreceptor tyrosine inhibitory motif (ITIM), a key region for transmitting inhibitory signals. This family contains five members (LILRB1-LILRB5).
LILRB binds to ligands such as MHC-l, ApoE, and Angptls, inducing ITIM tyrosine phosphorylation, thereby recruiting SHP-1/SHP-2 and SHIP phosphatases to dephosphorylate downstream kinases (Src, Syk, ZAP70, PI3K, etc.), ultimately inhibiting the activation, proliferation, and cytotoxicity of immune cells (such as T cells, NK cells, and macrophages), and promoting tumor immune escape. LILRB targets possess a unique mechanism of action, offering novel strategies for overcoming tumor immunotherapy challenges.
LILRBs are highly expressed in various solid tumors (such as lung cancer, breast cancer, and liver cancer) and hematological malignancies (such as acute myeloid leukemia and multiple myeloma), and are associated with tumor progression, immune escape, and poor prognosis. Meanwhile, members such as LILRB4 are abnormally expressed in autoimmune diseases such as systemic lupus erythematosus and Kawasaki disease, participating in immune tolerance and inflammation regulation. Monoclonal antibodies, CAR-T cells, and ADCs have entered clinical trials, and combining them with PD-1 inhibitors is becoming an important direction.

LILRB亚型特异性产品:LILRB Isoform Comparison
共 2种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
ES009

ES009 是一种高亲和力的 LILRB2 拮抗剂,对 hLILRB2-huANGPTL3 和 hLILRB2-huANGPTL4 的 IC50 分别为 14.07 nM 和 18.61 nM,它通过特异性阻断 LILRB2 与 MHC I 类及非 MHC 配体的相互作用来有效抑制受体激活,同时能重编程抗炎髓样细胞并促使其向促炎表型转化、逆转巨噬细胞介导的 T 细胞抑制作用,在与抗 PD-1 阻断疗法联用时还可协同增强 T 细胞活化,因此可用于晚期实体瘤及卵巢癌的相关研究。

Antagonist
ES009
Polzastobart
JTX 8064

Polzastobart (JTX-8064) 是一种人源化 IgG4 单克隆拮抗抗体,可选择性结合 LILRB2 并阻止其与配体、经典和非经典 MHC I 分子结合,通过阻断 LILRB2 结合 HLA-A/B 和/或 HLA-G(癌细胞免疫耐受标记)的能力来增强巨噬细胞中促炎细胞因子的产生,是一种巨噬细胞免疫检查点抑制剂。

2640981-19-5
Antagonist
97.81%
普泽苏拜单抗

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础